No Data
No Data
Bioxcel Therapeutics Executive Sells Over $148 in Stock
Mizuho Securities Maintains BioXcel Therapeutics(BTAI.US) With Hold Rating, Announces Target Price $1
Mizuho Securities analyst Graig Suvannavejh maintains $BioXcel Therapeutics(BTAI.US)$ with a hold rating, and sets the target price at $1.According to TipRanks data, the analyst has a success rate
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $7 Price Target
Bioxcel Therapeutics Earns Buy Rating on Promising Clinical Trials and Market Potential
Express News | BioXcel Therapeutics Inc - Trial Duration Expected to Be 9 to 12 Months
Express News | BioXcel Therapeutics Announces Initiation of Serenity at-Home Pivotal Phase 3 Safety Trial of Bxcl501 for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia